Toshinori Hinoue

Van Andel Institute

Full Professor(heuristic)

Bladder and Urothelial Cancer Treatments · Surgery

h-index54

i10-index67

Publications224

Citations66,237

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 59

Classification of non-TCGA cancer samples to TCGA molecular subtypes using compact feature sets
UNC Libraries · 2025-12-31
Figure S12 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
2025-11-25
Figure S8 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
2025-11-25
Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
2025-11-25
Figure S3 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
2025-11-25
Figure S5 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
2025-11-25
Figure S9 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
2025-11-25
Figure S7 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
2025-11-25
Figure S1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
2025-11-25
Figure S2 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
2025-11-25
Figure S4 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
2025-11-25
Figure S11 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
2025-11-25
Figure S10 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
2025-11-25
Figure S6 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
2025-11-25
Figure S1 from DAB2IP Is a Bifunctional Tumor Suppressor That Regulates Wild-Type RAS and Inflammatory Cascades in KRAS Mutant Colon Cancer
2025-11-24
Table S1, S2 from DAB2IP Is a Bifunctional Tumor Suppressor That Regulates Wild-Type RAS and Inflammatory Cascades in KRAS Mutant Colon Cancer
2025-11-24
High-coverage allele-resolved single-cell DNA methylation profiling reveals cell lineage, X-inactivation state, and replication dynamics
Nature Communications · 2025-07-07 · 6 citations
Abstract 6608: Integrating HCMI models and tumors with CCLE and TCGA: Advancing cancer modeling and precision oncology
Cancer Research · 2025-04-21
Abstract 1165: The landscape of molecular targets across 665 next-generation cancer models in the human cancer models initiative identifies opportunities for improved therapy and overcoming resistance
Cancer Research · 2025-04-21
Abstract 3882: Patterns of genomic patient-model conservation and evolution in the Human Cancer Models Initiative (HCMI) next-generation cancer model resource
Cancer Research · 2025-04-21

Open author page on OpenAlex →